Aldeyra Therapeutics (ALDX) Stock Forecast & Price Target

Aldeyra Therapeutics is viewed positively because its lead asset, reproxalap, has shown clinically meaningful activity across nine adequate and well-controlled trials, with five meeting all multiplicity-controlled primary endpoints, while also offering a differentiated profile as the only chronic dry eye drug with redness as a sign and rapid efficacy in chamber trials. The company’s decision to escalate through a Formal Dispute Resolution Request after repeated CRLs suggests it believes the evidence base is strong enough for a fresh regulatory review, especially since the original NDA was supported by six trials and the FDA acknowledged positive results in multiple studies. Beyond reproxalap, Aldeyra’s RASP-focused platform and pipeline in allergic conjunctivitis, retinal diseases, autoimmune disease, and cancer provide multiple shots on goal in large, underserved markets, supporting a de-risked long-term outlook.

Aldeyra Therapeutics is facing a materially weakened investment case because Reproxalap has now received another CRL, with the FDA citing lack of substantial evidence of efficacy, inconsistent study results, and an overall conclusion that the clinical package does not support effectiveness. The regulatory record also shows repeated setbacks from April 3, 2025 through March 16, 2026, including baseline imbalance concerns, a requested field-trial report, and reliance on a chamber trial after mixed dry eye data, which raises execution and approvability risk. With development-stage assumptions already reflecting 2032 EPS of $0.26 and exposure to financing and commercialization risk, the company’s pipeline remains highly uncertain and dependent on future capital and regulatory success.